Unveiling the Detrimental Effect of Glipizide on Structure and Function of Catalase: Spectroscopic, Thermodynamics

Mohd Shahnawaz Khan1, Nojood Al-Twaijry2, Fai N Alotaibi2

  • 1Department of Biochemistry, College of Science, King Saud University, 11451, Riyadh, Saudi Arabia. moskhan@ksu.edu.sa.

PubMed

Insights

Glipizide inhibits catalase activity, an enzyme that neutralizes harmful reactive oxygen species (ROS). This interaction shows potential for developing glipizide as a therapeutic agent against oxidative stress-related diseases.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Free radicals and reactive oxygen species (ROS) contribute to cellular damage in diseases like Parkinson's and diabetes.
  • Catalase is a key enzyme in scavenging ROS, making it a therapeutic target for oxidative stress-related conditions.
  • Understanding drug interactions with catalase is crucial for developing effective antioxidant strategies.

Purpose of the Study:

  • To investigate the interaction between bovine liver catalase and glipizide.
  • To evaluate the effect of glipizide on catalase enzymatic activity.
  • To explore the binding mechanism and structural changes of catalase upon glipizide complexation.

Main Methods:

  • Spectroscopic techniques (e.g., fluorescence, circular dichroism) were employed.
  • Computational methods, including molecular simulations, were utilized.
  • Enzymatic activity assays were performed to quantify catalase inhibition.

Main Results:

  • Glipizide inhibited catalase activity by over 20% at 50 µM.
  • Glipizide formed a complex with catalase with moderate affinity (binding constant 3.822–5.063 × 10⁴ M⁻¹).
  • Binding induced a slight increase in catalase's α-helical content and altered polarity around tryptophan residues.

Conclusions:

  • Glipizide acts as a moderate inhibitor of bovine liver catalase.
  • The binding is spontaneous and entropically favorable, with glipizide interacting with active site residues.
  • These findings suggest glipizide's potential as a catalase inhibitor for managing ROS-induced cellular damage.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
184
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
170
Enzymes02:34

Enzymes

Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
81.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152